Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$5 Mln
Net Profit (TTM)
$-28 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
24.51
EV/EBITDA
-0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
29,137,700
CFO
$-125.02 Mln
EBITDA
$-115.00 Mln
Net Profit
$-173.04 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
| -97.6 | -42.0 | -97.4 | -99.8 | -89.3 | -75.1 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
| -98.0 | 45.1 | 26.3 | 185.6 | -77.6 | -46.1 | -85.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
0.0 | 2.5 | 4.5 | -15.1 | -880.5 | -44.4 | -- | 0.6 |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 24.7 | 2,922.9 | 589.0 | 214.3 | 46.8 | 25.5 | 14.2 | 2.9 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related... strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey. On April 13, 2023, PLx Pharma Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Exec. Chairman
Mr. Michael J. Valentino
Exec. Chairman
Mr. Michael J. Valentino
Headquarters
Sparta, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of PLx Pharma Inc (PLXP) is $0.00 (NASDAQ) as of 14-Jun-2023 09:30 EDT. PLx Pharma Inc (PLXP) has given a return of -89.34% in the last 3 years.
Since, TTM earnings of PLx Pharma Inc (PLXP) is negative, P/E ratio is not available.
The P/B ratio of PLx Pharma Inc (PLXP) is 0.58 times as on 14-Jun-2023, a 90 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of PLx Pharma Inc (PLXP) are Rs -- and Rs -- as of 04-Apr-2026.
PLx Pharma Inc (PLXP) has a market capitalisation of $ 3 Mln as on 14-Jun-2023. As per SEBI classification, it is a company.
Before investing in PLx Pharma Inc (PLXP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.